{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T02:38:00Z","timestamp":1793587080089,"version":"4.5.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.euo.2025.01.003","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T21:17:38Z","timestamp":1737667058000},"page":"242-244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Implications and Lessons from the Withdrawal of Sacituzumab Govitecan for Treating Advanced Urothelial Carcinoma"],"prefix":"10.1016","volume":"8","author":[{"given":"David J.","family":"Benjamin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Rezazadeh Kalebasty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Mar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.01.003_b0005","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.01.003_b0010","unstructured":"Gilead Sciences, Inc. Gilead provides update on U.S. indication for Trodelvy\u00ae in metastatic urothelial cancer. https:\/\/www.gilead.com\/company\/company-statements\/2024\/gilead-provides-update-on-us-indication-for-trodelvy-in-metastatic-urothelial-cancer."},{"key":"10.1016\/j.euo.2025.01.003_b0015","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1016\/S1470-2045(23)00357-1","article-title":"Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?","volume":"24","author":"Cramer","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.01.003_b0020","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.23.01030","article-title":"National estimates of the participation of patients with cancer in clinical research studies based on commission on cancer accreditation data","volume":"42","author":"Unger","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.01.003_b0025","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2002.20.4.937","article-title":"Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer","volume":"20","author":"Vaughn","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.01.003_b0030","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1200\/JCO.1997.15.5.1853","article-title":"Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma","volume":"15","author":"McCaffrey","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.01.003_b0035","doi-asserted-by":"crossref","first-page":"S1096","DOI":"10.1016\/j.annonc.2024.08.1958","article-title":"1864P Study on the real-life use of G-CSF in patients with lung cancer: secondary data analysis from the French national cohorts KBP-2020-CPHG and ESCAP-2020-CPHG","volume":"35","author":"Debieuvre","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.01.003_b0040","doi-asserted-by":"crossref","first-page":"S1505","DOI":"10.1016\/j.annonc.2024.10.830","article-title":"LBA9 TROPiCS-04, a randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (CT) in pretreated advanced urothelial carcinoma (aUC): overall survival (OS) and safety analysis","volume":"35","author":"Grivas","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.01.003_b0045","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(22)00193-0","article-title":"Accelerated approval requirements for lurbinectedin","volume":"23","author":"Benjamin","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.01.003_b0050","article-title":"Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study","volume":"374","author":"Gyawali","year":"2021","journal-title":"BMJ"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T09:51:51Z","timestamp":1744883511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125000033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2588931125000033"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.01.003","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implications and Lessons from the Withdrawal of Sacituzumab Govitecan for Treating Advanced Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}